Silence Therapeutics (SLN) Return on Assets: 2021-2025
Historic Return on Assets for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to -0.41%.
- Silence Therapeutics' Return on Assets rose 16.00% to -0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.41%, marking a year-over-year increase of 16.00%. This contributed to the annual value of -0.28% for FY2024, which is 46.00% up from last year.
- Latest data reveals that Silence Therapeutics reported Return on Assets of -0.41% as of Q3 2025, which was up 8.37% from -0.45% recorded in Q2 2025.
- Silence Therapeutics' 5-year Return on Assets high stood at -0.28% for Q4 2024, and its period low was -7.40% during Q1 2022.
- For the 3-year period, Silence Therapeutics' Return on Assets averaged around -1.15%, with its median value being -0.45% (2025).
- Per our database at Business Quant, Silence Therapeutics' Return on Assets skyrocketed by 476bps in 2023 and then fell by 9bps in 2025.
- Silence Therapeutics' Return on Assets (Quarterly) stood at -3.71% in 2021, then reached -7.40% in 2022, then surged by 476bps to -0.86% in 2023, then spiked by 59bps to -0.28% in 2024, then climbed by 16bps to -0.41% in 2025.
- Its Return on Assets stands at -0.41% for Q3 2025, versus -0.45% for Q2 2025 and -0.37% for Q1 2025.